Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Traws Pharma ( (TRAW) ) has issued an announcement.
On June 30, 2025, Traws Pharma announced multiple regulatory submissions related to its antiviral pipeline, which includes potential first-in-class and best-in-class therapies for bird flu and COVID-19. This development is part of Traws Pharma’s strategy to enhance its market position by addressing critical viral threats and expanding the U.S. strategic stockpile with innovative treatments. The announcement reflects the company’s ongoing efforts to maximize the efficacy and safety of its next-generation antivirals while overcoming resistance to existing agents.
The most recent analyst rating on (TRAW) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. operates in the pharmaceutical industry, focusing on developing small molecule antiviral drugs targeting respiratory viruses with pandemic potential. The company is actively seeking development and commercialization partners for its legacy oncology assets and is supported by recognized institutional investors.
Average Trading Volume: 1,185,408
Technical Sentiment Signal: Sell
Current Market Cap: $7.96M
For detailed information about TRAW stock, go to TipRanks’ Stock Analysis page.